Surveillance for pancreatic cancer in high-risk individuals.


Journal

BJS open
ISSN: 2474-9842
Titre abrégé: BJS Open
Pays: England
ID NLM: 101722685

Informations de publication

Date de publication:
10 2019
Historique:
received: 28 12 2018
accepted: 02 04 2019
entrez: 9 10 2019
pubmed: 9 10 2019
medline: 9 10 2019
Statut: epublish

Résumé

Surveillance of individuals at high risk of pancreatic ductal adenocarcinoma (PDAC) and its precursors might lead to better outcomes. The aim of this study was to determine the prevalence and outcomes of PDAC and high-risk neoplastic precursor lesions among such patients participating in surveillance programmes. A multicentre study was conducted through the International CAncer of the Pancreas Screening (CAPS) Consortium Registry to identify high-risk individuals who had undergone pancreatic resection or progressed to advanced PDAC while under surveillance. High-risk neoplastic precursor lesions were defined as: pancreatic intraepithelial neoplasia (PanIN) 3, intraductal papillary mucinous neoplasia (IPMN) with high-grade dysplasia, and pancreatic neuroendocrine tumours at least 2 cm in diameter. Of 76 high-risk individuals identified in 11 surveillance programmes, 71 had undergone surgery and five had been diagnosed with inoperable PDAC. Of the 71 patients who underwent resection, 32 (45 per cent) had PDAC or a high-risk precursor (19 PDAC, 4 main-duct IPMN, 4 branch-duct IPMN, 5 PanIN-3); the other 39 patients had lesions thought to be associated with a lower risk of neoplastic progression. Age at least 65 years, female sex, carriage of a gene mutation and location of a lesion in the head/uncinate region were associated with high-risk precursor lesions or PDAC. The survival of high-risk individuals with low-risk neoplastic lesions did not differ from that in those with high-risk precursor lesions. Survival was worse among patients with PDAC. There was no surgery-related mortality. A high proportion of high-risk individuals who had surgical resection for screening- or surveillance-detected pancreatic lesions had a high-risk neoplastic precursor lesion or PDAC at the time of surgery. Survival was better in high-risk individuals who had either low- or high-risk neoplastic precursor lesions compared with that in patients who developed PDAC. Se podrían obtener mejores resultados con el seguimiento de individuos de alto riesgo para adenocarcinoma ductal pancreático ( Se llevó a cabo un estudio multicéntrico a través del registro internacional del consorcio CAPS ( De 76 individuos con lesiones de alto riesgo identificados en 11 programas de seguimiento, 71 fueron tratados quirúrgicamente y 5 fueron diagnosticados de un PDAC inoperable. De las 71 resecciones, 32 (45%) tenían PDAC o una lesión precursora de alto riesgo (19 PDAC, 4 IPMN de conducto principal, 4 IPMN de rama secundaria y 5 PanIN‐3). Los otros 39 pacientes tenían lesiones que se consideraron asociadas con un menor riesgo de progresión neoplásica. La edad ≥ 65 años, el sexo femenino, el ser portador de una mutación genética y la localización de la lesión en la cabeza/proceso uncinado fueron factores asociados a las lesiones precursoras de alto riesgo o al PDAC. No hubo diferencias en la supervivencia de individuos de alto riesgo con lesiones neoplásicas de bajo riesgo frente a aquellos que presentaron lesiones precursoras de alto riesgo. La supervivencia fue peor en los pacientes con PDAC. No hubo mortalidad relacionada con la cirugía. Un elevado porcentaje de individuos de alto riesgo que se sometieron a resección quirúrgica tras la detección de lesiones pancreáticas en el seguimiento tenían una lesión precursora neoplásica de alto riesgo o un PDAC. La supervivencia fue mejor en individuos de alto riesgo que tenían lesiones precursoras neoplásicas de bajo o alto riesgo en comparación con aquellos pacientes que habían desarrollado un PDAC.

Sections du résumé

Background
Surveillance of individuals at high risk of pancreatic ductal adenocarcinoma (PDAC) and its precursors might lead to better outcomes. The aim of this study was to determine the prevalence and outcomes of PDAC and high-risk neoplastic precursor lesions among such patients participating in surveillance programmes.
Methods
A multicentre study was conducted through the International CAncer of the Pancreas Screening (CAPS) Consortium Registry to identify high-risk individuals who had undergone pancreatic resection or progressed to advanced PDAC while under surveillance. High-risk neoplastic precursor lesions were defined as: pancreatic intraepithelial neoplasia (PanIN) 3, intraductal papillary mucinous neoplasia (IPMN) with high-grade dysplasia, and pancreatic neuroendocrine tumours at least 2 cm in diameter.
Results
Of 76 high-risk individuals identified in 11 surveillance programmes, 71 had undergone surgery and five had been diagnosed with inoperable PDAC. Of the 71 patients who underwent resection, 32 (45 per cent) had PDAC or a high-risk precursor (19 PDAC, 4 main-duct IPMN, 4 branch-duct IPMN, 5 PanIN-3); the other 39 patients had lesions thought to be associated with a lower risk of neoplastic progression. Age at least 65 years, female sex, carriage of a gene mutation and location of a lesion in the head/uncinate region were associated with high-risk precursor lesions or PDAC. The survival of high-risk individuals with low-risk neoplastic lesions did not differ from that in those with high-risk precursor lesions. Survival was worse among patients with PDAC. There was no surgery-related mortality.
Conclusion
A high proportion of high-risk individuals who had surgical resection for screening- or surveillance-detected pancreatic lesions had a high-risk neoplastic precursor lesion or PDAC at the time of surgery. Survival was better in high-risk individuals who had either low- or high-risk neoplastic precursor lesions compared with that in patients who developed PDAC.
Antecedentes
Se podrían obtener mejores resultados con el seguimiento de individuos de alto riesgo para adenocarcinoma ductal pancreático (
Métodos
Se llevó a cabo un estudio multicéntrico a través del registro internacional del consorcio CAPS (
Resultados
De 76 individuos con lesiones de alto riesgo identificados en 11 programas de seguimiento, 71 fueron tratados quirúrgicamente y 5 fueron diagnosticados de un PDAC inoperable. De las 71 resecciones, 32 (45%) tenían PDAC o una lesión precursora de alto riesgo (19 PDAC, 4 IPMN de conducto principal, 4 IPMN de rama secundaria y 5 PanIN‐3). Los otros 39 pacientes tenían lesiones que se consideraron asociadas con un menor riesgo de progresión neoplásica. La edad ≥ 65 años, el sexo femenino, el ser portador de una mutación genética y la localización de la lesión en la cabeza/proceso uncinado fueron factores asociados a las lesiones precursoras de alto riesgo o al PDAC. No hubo diferencias en la supervivencia de individuos de alto riesgo con lesiones neoplásicas de bajo riesgo frente a aquellos que presentaron lesiones precursoras de alto riesgo. La supervivencia fue peor en los pacientes con PDAC. No hubo mortalidad relacionada con la cirugía.
Conclusión
Un elevado porcentaje de individuos de alto riesgo que se sometieron a resección quirúrgica tras la detección de lesiones pancreáticas en el seguimiento tenían una lesión precursora neoplásica de alto riesgo o un PDAC. La supervivencia fue mejor en individuos de alto riesgo que tenían lesiones precursoras neoplásicas de bajo o alto riesgo en comparación con aquellos pacientes que habían desarrollado un PDAC.

Autres résumés

Type: Publisher (spa)
Se podrían obtener mejores resultados con el seguimiento de individuos de alto riesgo para adenocarcinoma ductal pancreático (

Identifiants

pubmed: 31592073
doi: 10.1002/bjs5.50180
pii: BJS550180
pmc: PMC6773633
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Pagination

656-665

Informations de copyright

© 2019 The Authors. BJS Open published by John Wiley & Sons Ltd on behalf of BJS Society Ltd.

Références

Clin Cancer Res. 2010 Oct 15;16(20):5028-37
pubmed: 20876795
Int J Epidemiol. 1982 Sep;11(3):261-7
pubmed: 7129740
Clin Cancer Res. 2013 Jan 15;19(2):442-9
pubmed: 23172884
Gastroenterology. 2012 Apr;142(4):796-804; quiz e14-5
pubmed: 22245846
Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665
pubmed: 16682259
Pancreatology. 2017 Mar - Apr;17(2):267-272
pubmed: 28117220
J Clin Oncol. 2016 Jun 10;34(17):2010-9
pubmed: 27114589
J Gastrointest Surg. 2012 Apr;16(4):771-83
pubmed: 22127781
Am J Surg Pathol. 2006 Sep;30(9):1067-76
pubmed: 16931950
Am J Gastroenterol. 2009 Sep;104(9):2175-81
pubmed: 19491823
Am J Gastroenterol. 2011 May;106(5):946-54
pubmed: 21468009
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Gastrointest Endosc. 2002 Oct;56(4 Suppl):S82-6
pubmed: 12297755
Am Surg. 2016 Aug;82(8):737-42
pubmed: 27657591
Gut. 2016 Sep;65(9):1505-13
pubmed: 25986944
Gastroenterology. 2011 Mar;140(3):850-6
pubmed: 21129377
Gut. 2013 Mar;62(3):339-47
pubmed: 23135763
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
J Surg Oncol. 2013 Jan;107(1):97-103
pubmed: 22991309
J Gastrointest Surg. 2013 Dec;17(12):2105-13
pubmed: 24101447
Cancer Discov. 2016 Feb;6(2):166-75
pubmed: 26658419
Fam Cancer. 2011 Jun;10(2):323-30
pubmed: 21207249
Clin Gastroenterol Hepatol. 2017 Oct;15(10):1509-1520.e4
pubmed: 28342950
Semin Oncol. 1996 Apr;23(2):251-75
pubmed: 8623061

Auteurs

I C A W Konings (ICAW)

Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, the Netherlands.

M I Canto (MI)

Department of Gastroenterology and Hepatology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.

J A Almario (JA)

Department of Gastroenterology and Hepatology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.

F Harinck (F)

Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, the Netherlands.

P Saxena (P)

Department of Gastroenterology and Hepatology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
Department of Gastroenterology and Hepatology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

A L Lucas (AL)

Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, USA.

F Kastrinos (F)

Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, USA.

D C Whitcomb (DC)

Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

R E Brand (RE)

Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

J Lachter (J)

Department of Gastroenterology, Rambam Healthcare Campus, Haifa, Israel.

G Malleo (G)

Department of General Surgery, University Hospital of Verona, Verona, Italy.

S Paiella (S)

Department of General Surgery, University Hospital of Verona, Verona, Italy.

S Syngal (S)

Department of Gastroenterology, Brigham and Women's Hospital and Population Sciences Division, Dana Farber Cancer Institute, Boston, Massachusetts, USA.

J R Saltzman (JR)

Department of Gastroenterology, Brigham and Women's Hospital and Population Sciences Division, Dana Farber Cancer Institute, Boston, Massachusetts, USA.

E M Stoffel (EM)

Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.

J E van Hooft (JE)

Department of Gastroenterology and Hepatology, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.

R H Hruban (RH)

Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland.

J W Poley (JW)

Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, the Netherlands.

P Fockens (P)

Department of Gastroenterology and Hepatology, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.

M G Goggins (MG)

Department of Gastroenterology and Hepatology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.

M J Bruno (MJ)

Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH